Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
May 26, 2026Toronto, ON - May 26, 2026 — Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has approved IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel 3%), a topical ophthalmic anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures in adults.1
With approval granted, IHEEZO™ will be available to Canadian healthcare professionals as a sterile, preservative-free gel formulation supplied in single-use vials. IHEEZO™ is intended for administration by qualified eye care clinicians only and is not for patient self-administration.
"This approval reflects our commitment to supporting Canadian healthcare professionals with high-quality medicines that meet important clinical needs,” said Martin Arès, President, Apotex Canada and Rest of World (ROW). “Ocular care is an essential area of clinical practice, and we are proud to introduce IHEEZO™ as another approved option within our ophthalmic portfolio, alongside Verkazia®, Clobivis™ and Aflivu, Apotex's aflibercept biosimilar. Together, these medicines reflect our growing presence in ocular care and reinforce our ongoing contribution to a strong and reliable healthcare system for patients nationwide."
Healthcare professionals should consult the complete Product Monograph for detailed information on dosing, administration, warnings, precautions, and adverse reactions.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Learn more at www.apotex.com.
1Product Monograph: https://dhpp.hpfb-dgpsa.ca/dhpp/resource/107066
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.